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Abstract: Inflammation is a complex, multi-scale biologic
response to stress that is also required for repair and
regeneration after injury. Despite the repository of
detailed data about the cellular and molecular processes
involved in inflammation, including some understanding
of its pathophysiology, little progress has been made in
treating the severe inflammatory syndrome of sepsis. To
address the gap between basic science knowledge and
therapy for sepsis, a community of biologists and
physicians is using systems biology approaches in hopes
of yielding basic insights into the biology of inflammation.
‘‘Systems biology’’ is a discipline that combines experi-
mental discovery with mathematical modeling to aid in
the understanding of the dynamic global organization
and function of a biologic system (cell to organ to
organism). We propose the term translational systems
biology for the application of similar tools and engineering
principles to biologic systems with the primary goal of
optimizing clinical practice. We describe the efforts to use
translational systems biology to develop an integrated
framework to gain insight into the problem of acute
inflammation. Progress in understanding inflammation
using translational systems biology tools highlights the
promise of this multidisciplinary field. Future advances in
understanding complex medical problems are highly
dependent on methodological advances and integration
of the computational systems biology community with
biologists and clinicians.
Introduction: Inflammation Is a Complex System
Inflammation is a finely tuned, dynamic process, and its
dysregulation underlies many complex diseases (e.g., sepsis,
infectious disease, trauma, asthma, allergy, autoimmune disorders,
transplant rejection, cancer, neurodegenerative diseases, obesity,
and atherosclerosis). However, inflammation is not inherently
detrimental. Inflammatory processes are required for immune
surveillance, optimal repair, and regeneration after injury [1–3].
Inflammation is itself also a complex process, and like other
complex systems, it has defied reductionist, linear definition [4–7].
Unfortunately, because a global definition or understanding of
inflammation has not emerged from enormous data generated in
basic biology, this deep dataset has not translated into mechanistic
understanding sufficient to predict system behavior, and little in
the way of effective therapies has emerged.
The discrepancy between biologic data and therapy has
hampered the search for adequate clinical approaches in the
settings of various inflammation-related disorders. More specifi-
cally and recognizing this discrepancy, the NIH Roadmap recently
underscored the need to apply systems biology methods to the
study of inflammation [8]. These methods include computational,
mathematical, and engineering approaches (in silico methods) to
facilitate translation of biomedical research.
Systems biology has been defined in many ways [9–11], but
generally is considered a global analytic approach to biologic data
at the multiple scales of organization that characterize biologic
systems, with the goal of identifying specific genetic and molecular
signatures for improved diagnosis of disease [12–21]. Despite the
richness of these approaches, there is still a relative paucity of
techniques that transcend and describe the multiple scales and
hierarchies of organization in a way that leads to effective
therapeutic strategies. For instance, high throughput analyses
(genomics, proteomics) have identified myriad factors and
pathways involved in inflammation. However, the plethora of
reductionist studies that these approaches were expected to replace
have generated enormous amounts of data, but little in the way of
translational insights necessary to use the data clinically. These
high-throughput analyses rely on statistical methods for data
interpretation and pattern analysis. We suggest that statistical
methods must be augmented with dynamic modeling and
simulation, along with mathematical tools from engineering, in
order to address organization and behavior of dynamic complex
disease processes. The goal of integrating these tools is to generate
disease models that can be used for rapid translation, in areas as
diverse as in silico clinical trials, diagnostics, and rational drug
design. In addition, systems biology approaches can also yield
fundamental insights into the mechanistic determinants of
complex biologic processes. Further, we suggest the need to
modify the way computational simulation is currently implement-
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ed to best address issues of direct clinical relevance, since to date
computational and simulation technologies have been mostly
utilized in the context of examining subcellular and cellular
processes (Table 1, Figure 1) [9,22,23]. In order to translate the
varied data streams from basic science into organism-level insights,
the data must be organized into mechanistic, dynamical models to
simulate higher-level (total organism) behavior and response to
interventions. Translational systems biology requires that mathe-
matical and modeling expertise be combined with expertise in
various biological specialties and medical specialties.
Below, we detail the approaches used and salient findings
observed thus far in the translational systems biology of
inflammation. These studies have been applied to acute inflam-
matory responses including sepsis, trauma, hemorrhagic shock,
and wound healing [7,24–34], largely carried out under the aegis
of the Society of Complexity in Acute Illness (SCAI, http://www.
scai-med.org). Similar approaches are at the heart of many efforts,
especially in industry, where there is an acute need for rational
drug candidate discovery and improved efficiency in the transition
from candidate compound to clinical trial [35]. However, the
inflammation field is the first in which the translational systems
biology framework has been a guiding principle applied in a
systematic fashion. The primary methods of dynamic mathemat-
ical modeling utilized in these studies are agent-based modeling
(ABM) [24,25,36] and equation-based modeling (EBM), the latter
encompassing primarily ordinary differential equations (ODE) and
partial differential equations (PDE) [26–31,37–40]. The two forms
of dynamic mathematical modeling have their respective strengths
and weaknesses [7], but the utilization of both methods in the work
described below demonstrates a pragmatic, goal-directed ap-
proach not tied to a particular modeling platform [7].
Applications of Translational Systems Biology in
Acute Inflammation: From Man to Mouse to Man
Translational systems biology has developed largely in response
to the clinical challenge of sepsis. Sepsis is a syndrome resulting
from massive, acute activation of the inflammatory response,
traditionally in the setting of severe infection. Sepsis syndromes
can often complicate trauma and/or hemorrhagic shock. In its
most severe form, sepsis results in low blood pressure with
insufficient perfusion of organs, and leads to multiple organ failure
and death. Initial modeling studies were therefore focused on the
pathophysiology of the acute inflammatory response to stress, and
these studies pointed to common underlying processes generated
in response to infection, injury, and shock. Later, as the modeling
efforts matured to include the recovery phase of injury, the major
insight gained was the link between the initial inflammatory
Table 1. Comparison of Classical and Translational Systems Biology.
Classical Systems Biology Translational Systems Biology
Basic insights are primary focus, i.e., ‘‘drilling down’’ Translational insights are primary focus, i.e., ‘‘building up’’
Models structured for greatest basic insights (cellular/molecular interactions,
signal transduction pathways)
Models structured for clinical translational utility (in silico clinical trials, diagnostics,
rational drug/device design)
Simulations designed for laboratory validation Simulations designed for eventual clinical validation
‘‘omics’’ studies applied to clinically relevant situations, and subsequently
subjected to statistical analysis
Mechanistic simulations of whole-organism response guide ‘‘-omics’’ studies
doi:10.1371/journal.pcbi.1000014.t001
Figure 1. Overview of Translational Systems Biology. Pre-existing knowledge from the literature and newly generated information from wet
lab experiments lead to the development of dynamic mathematical models. These computational simulations can then lead to both knowledge
discovery, in the form of basic insights, and translational usage, such as in silico experiments and other engineering processes.
doi:10.1371/journal.pcbi.1000014.g001
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response and subsequent recovery (healing). Here we present a
history of how this field evolved around the seemingly intractable
problem of sepsis, focusing on the rationale for the studies and
insights derived from them.
Sepsis was the motivating clinical problem that led to
mathematical modeling of inflammation. Intensive care physicians
recognize that sepsis therapy has not changed substantially for
decades despite an enormous amount of data generated from in
vitro and animal studies, as well as from clinical studies [41–44].
The first approaches were designed to answer the question, ‘‘What
are the dynamics of sepsis, and does our lack of therapies imply
some yet undiscovered mediator of the syndrome?’’ In mainstream
biology and biotechnology, this question motivates the ongoing
search for a ‘‘magic bullet’’ to treat sepsis. The translational
systems biology formulation of the question, though, was reworded
to reflect a different philosophical approach to research, i.e., ‘‘Is
the current state of knowledge insufficient to explain observed
clinical behaviors?’’ Thus, the missing knowledge was assumed not
to be a missing molecule or pathway, rather the missing knowledge
was assumed to be an understanding of how all the various
components involved in the sepsis response are organized and how
they interact to generate a behavior. This question led to the use of
ABM as a knowledge representation tool, constructed by reviewing
the literature describing the molecular and cellular components of
the acute inflammatory response. This model conceptualized
inflammation as the interaction between endothelium (the single
layer of cells that line blood vessels and delineate the vessel’s
lumen) and blood-borne inflammatory cells [24,36], treating the
whole organism as a gigantic endothelial cell surface over which
inflammatory cells moved and interacted. Despite its abstraction,
this model was able to qualitatively reproduce patterns of diverse
clinical outcomes in sepsis [24]. In so doing, this model addressed
certain controversial questions with respect to the dynamics of
sepsis. The first of these was whether the anti-inflammatory
response represented a subsequent and compensatory response to
the initial pro-inflammatory response, or whether the pro- and
anti-inflammatory responses were initiated concurrently. In the
construction of ABM, no mechanistic evidence could be found to
justify a defined ‘‘lag’’ in the anti-inflammatory response;
published evidence at the time suggested that both pro- and
anti-inflammatory cellular responses were triggered by the same
stimuli. Instantiating those rules dynamically demonstrated that
the anti-inflammatory response [represented by interleukin-10 (IL-
10) levels] was indeed concurrent with the acute pro-inflammatory
response [represented by interleukin-1 (IL-1) and tumor necrosis
factor-a (TNF-a) levels]. The second interesting behavior
uncovered by the model (now generally recognized) was that
patients who suffered from the immune-suppressed phenotype of
late-stage multiple organ failure and were susceptible to usually
trivial nosocomial infections demonstrated sustained elevated
markers of tissue damage and inflammation through two weeks
of simulated time [29–30]. While this pattern seems obvious now,
anti-cytokine drug trials had treatment protocols spanning only a
single dose or a single day. Thus, this phenomenon (even if
recognized) was not incorporated into the trial design, perhaps
contributing to the failure of these candidate therapies.
The other initial modeling approach to sepsis took concepts used
in ABM (restoring connections, representing concurrent processes
and feedback loops) into qualitative EBM that described major
phenomena in sepsis such as the role of anti-inflammatory responses
and the paradoxical effects of pre-conditioning (in which two
nominally pro-inflammatory stimuli can result in synergy or
suppression relative to each stimulus alone) [37–39]. This work led
to the creation of larger EBM calibrated with data obtained in the
animal laboratory [27], with the premise that mathematical models
require experimental validation and feedback between the models
and experiments. The mouse studies were carried out for the express
purpose of calibrating global EBM of acute inflammation, and
confirmed the nearly simultaneous elaboration of the cytokines
TNF-a and IL-10 after endotoxin (bacterial product) or trauma/
hemorrhage. The base EBM was adjusted to match the initial
conditions for both endotoxin challenge and trauma/hemorrhage.
In each case, the subsequently generated, simulated cytokine profiles
matched the wet lab patterns for each experimental preparation
[27]. The model was sufficient to extrapolate in silico simulated data
to prospective prediction of the threshold dose at which endotoxin
would be lethal in mice, showing that information could be gleaned
from the model beyond its calibration dataset [27].
Furthermore, in the process of calibrating this model to trauma/
hemorrhage, we observed that the simulation of shock and global
tissue ischemia/reperfusion was not reproducing the intensity or
lethality of the inflammatory response in mice. The reason for the
insufficiency of the model was that it did not reflect the practical
issues in the animal model: it is impossible to have hemorrhage in the
animal without some tissue injury. When a relatively trivial trauma
(for extracting blood) was introduced into the simulation, the
inflammatory mediator and lethality profiles seen in the mouse
experiments were reproduced [30]. These findings along with
parallel high throughput analysis of gene expression patterns (below)
were incorporated into the in silico models, and ultimately led to the
important conclusion that hemorrhage was not the driving response
in acute inflammation after trauma/hemorrhage. Rather, the
surgical trauma was the major signal initiating inflammation, leading
to organ damage. These results show that the model development
process alone can lead to interesting mechanistic insights into systems
behavior. At the time, most specialists in the field thought that global
ischemia/reperfusion was the predominant factor driving the
inflammatory response to hemorrhagic shock.
We developed increasingly complex models of inflammation for
quantitative prediction of circulating cytokine levels in rats, swine,
and humans [28]. Other investigators, recognizing the clinical
importance of these models, used EBM to describe the dynamics
of bacterial growth in experimental pneumonia [31], and simulate
the inflammatory response of influenza [34]. Different EBM was
used to examine the nonlinear interactions between antibiotics and
vaccination in the setting of anthrax infection [32]. EBM has also
been used to study various facets of the inflammatory response to
burn trauma, including the effects of resuscitation and cell-based
therapy [45–52].
The Golden Fleece: In Silico Clinical Trials for
Sepsis
An important application of translational systems biology is use of
simulations similar to those described above in the design and
structuring of clinical trials. If successful, these tools have the potential
to fundamentally transform the way clinical trials are conducted for
acute inflammatory states such as sepsis and trauma. Simulations of
clinical trial outcomes yield analysis of the patient subpopulations
helped, harmed, or unaffected by a clinical intervention [26]. This
type of sub-stratification of patients who deserve certain therapies is
just now recognized as an important factor in clinical care. By
incorporating genomic data, the simulations can be used to
prospectively classify patients as appropriate recipients of a particular
intervention (‘‘personalized medicine’’).
Translational systems biology has prompted development of
methods to link extensive data on gene regulation and control to
clinically relevant conditions. For example, EBM has been used to
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distinguish between the scale of gene expression (how much of
each gene is expressed) and the scope of gene expression (number
of pathways recruited) based on the severity of the insult [30]. The
next step in modeling behavior of the inflammatory response,
then, is likely to be incorporation of whole-genome expression
levels coupled to network/pathway analysis in the model [13,53],
with in vivo validation in appropriate mouse models (such as mice
with specific genes deleted [53]). In turn, the modified mathemat-
ical models that help define the role of a given gene product [29]
could be further validated with in silico clinical trials [25,26,32] to
determine whether the gene product is a valid therapeutic target.
Modeling has been integrated into actual trial design by utilizing
the iterative process common to engineering projects, consisting of
a knowledge/development loop between the real-world data and
the simulation as the information from one source feeds into the
next [28]. Models thus refined have already been used to assist in
the analysis of ongoing clinical trials. In one case, the models
produced a ‘‘virtual’’ placebo arm for an open-label Phase IV drug
trial, providing an additional comparison for the actual Phase IV
results and the preceding Phase III trial [54]. These examples used
models to focus on efficacy of a single therapeutic intervention,
and therefore were limited in scope, but the predictive value of the
models is nonetheless evidence that translational systems biology
approaches can have significant impact on the design and
implementation of actual clinical therapies.
After the Injury: The Link between Inflammation
and Healing
We next turned our attention to the recovery phase, healing
after acute inflammation. Wound healing (obviously part of
trauma, but also often associated with sepsis) involves interaction
of inflammatory mediators with mediators of the tissue remodeling
and regenerative responses [1,2,55–60]. The early models of
wound healing were built around epithelial proliferation and
migration [61–70], followed by construction of a series of ABM
incorporating interactions between regulators of inflammation and
remodeling. These models were used to study necrotizing
enterocolitis (NEC), a severe inflammatory intestinal disease of
newborns [71,72]. The regenerative process necessary both for
reversal of the inflammatory response and for recovery from NEC
involves migration of healthy enterocytes to sites of mucosal
disruption [71]. PDE models of this process incorporated spatial
effects such as diffusion of inflammatory agents, chemotaxis of
both bacteria and inflammatory cells, and enterocyte migration
[72]. The main insight gained by incorporation of these features
into the model was that inflammation induced by an initial
hypoxic/traumatic insult could be propagated by bacterial efflux
through damaged epithelium.
To this point we have discussed models of acute inflammation,
but chronic inflammation is also a major factor in impaired would
healing, as in diabetes [2,59,73]. We modeled the relationship
between inflammation and healing using ABM of diabetic foot
ulcers [33]. Skin inflammation and healing in these wound models
was calibrated to literature parameters. Single hypothesized,
diabetes-related derangements in inflammatory mediators or
factors involved in wound healing (namely, elevation of TNF-a
and/or reduction of bioactive transforming growth factor-b1) were
used in the model to predict delayed healing. The model
recapitulated the beneficial effects of well-known therapies for
diabetic foot ulcers—debridement and platelet-derived growth
factor—and suggested novel therapies [33]. This particular
example of computational simulation of a disease process
highlights the potential to investigate results of both routine non-
pharmacologic and pharmacologic interventions.
Conclusions and Future Prospects
The literature on inflammation has yielded an enormous parts
list of mediators and important information on how these
mediators are linked to each other, but the entire range of
inflammatory conditions has not been organized in a way that
allows interpretation of data for design of clinical studies, or virtual
manipulation of the system. This gap between experimentally
derived details and application of knowledge to the bedside is
being addressed by the translational systems biology community.
This new field is developing binding methods, such as a syntactical
modeling grammar that expresses hypotheses in formal logical
syntax [74] to facilitate model construction and to improve the
predictive clinical accuracy of models of inflammation.
Successful translation of models into practice requires further
studies in several areas. For example, models are currently built
and modified through a painstaking and time-consuming manual
curation of the scientific literature. Certainly translational systems
biology will benefit from automation of this process for mining
data in a form that supports continuous updating of models.
Similarly, non-mathematically trained clinicians often struggle
with converting their intuitive biologic models into mathematic
models using software developed for mathematicians. Transla-
tional systems biology needs improved software for facilitating
translation of clinical knowledge into mathematical models.
If successful, these and other efforts will lead to model-driven
design and testing of new therapies, clinical trials that are preceded
by dry runs in silico, mathematical models to support diagnosis
and therapy of critically ill patients, and outpatient plans
developed using model-driven decisions along a continuum of
care. Within a systems framework, these fragmented procedures
can be treated as an integrated whole, in which biology-motivated
mathematical models are used at every stage. The therapeutic
utility of such approaches is treated with some skepticism now
[75], but progress in understanding the complexity of inflamma-
tion should afford some optimism that, with input from the
computational/systems biology community, translational systems
biology efforts can lead to fundamental insights into optimal
therapies.
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